Journal
CLINICAL CANCER RESEARCH
Volume 20, Issue 5, Pages 1064-1066Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-13-3194
Keywords
-
Categories
Funding
- Translational Sarcoma Research Network (TransSaRNet) Funding Program of the Federal Ministry of Education and Research BMBF, Federal Republic of Germany [01GM0870]
- Prospective Validation of Biomarkers in Ewing Sarcoma for Personalised Translational Medicine (PROVABES) Funding Program of the Federal Ministry of Education and Research BMBF, Federal Republic of Germany [01KT1311]
- Wilhelm Sander Stiftung [2009.901.1]
- TransAid Foundation [13/0506]
- CuraPlacida Foundation [CP101/120714]
Ask authors/readers for more resources
Cytotoxic drugs may have specific effects on oncogenes and their downstream targets. Increase of cancer cell sensitivity due to repression of an oncogene downstream target can be specifically addressed by combined precision chemotherapy, increasing the therapeutic index of chemotherapy and overcoming resistance to highly selective targeted therapies. (C) 2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
